175 related articles for article (PubMed ID: 15982417)
1. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance.
Trejo-Becerril C; Oñate-Ocaña LF; Taja-Chayeb L; Vanoye-Carlo A; Cetina L; Duenas-Gonzalez A
BMC Cancer; 2005 Jun; 5():65. PubMed ID: 15982417
[TBL] [Abstract][Full Text] [Related]
2. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
3. Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility.
Distefano M; Ferrandina G; Smaniotto D; Margariti AP; Zannoni G; Macchia G; Manfredi R; Mangiacotti MG; Cellini N; Scambia G
Oncology; 2004; 67(2):103-11. PubMed ID: 15539913
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of neoadjuvant paclitaxel-carboplatin chemotherapy followed by radical hysterectomy compared to radical hysterectomy alone in bulky stage IB2-IIA cervical cancer.
Prueksaritanond N; Chaisarn P; Yanaranop M
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S55-61. PubMed ID: 22619888
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
[TBL] [Abstract][Full Text] [Related]
6. Wertheim's hysterectomy after neoadjuvant carboplatin-based chemotherapy in patients with cervical cancer stage IIB and IIIB.
Meden H; Fattahi-Meibodi A; Osmers R; Krauss T; Kuhn W
Anticancer Res; 1998; 18(6B):4575-9. PubMed ID: 9891521
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
8. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Yin M; Zhang H; Li H; Li X; Liu Y; Chen X; Lou G; Li K
J Surg Oncol; 2012 Feb; 105(2):206-11. PubMed ID: 21815150
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
11. [Comparative analysis of neoadjuvant therapies in stage Ib2 and IIa2 cervical carcinoma].
Hu JL; Wu LY; Li N; Li XG; Huang MN; Zhang R
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):452-7. PubMed ID: 22932113
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
Zhang R; Li B; Bai P; Li HJ; Li SM; Wu LY; Li W
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):616-20. PubMed ID: 22325224
[TBL] [Abstract][Full Text] [Related]
13. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Lee JY; Kim YH; Kim MJ; Kim K; Chung HH; Park NH; Song YS; Kang SB
Arch Gynecol Obstet; 2011 Aug; 284(2):477-82. PubMed ID: 20878172
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix.
Serur E; Mathews RP; Gates J; Levine P; Maiman M; Remy JC
Gynecol Oncol; 1997 May; 65(2):348-56. PubMed ID: 9159350
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report.
Fuso L; Mazzola S; Marocco F; Ferrero A; Dompè D; Carus AP; Zola P
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S187-91. PubMed ID: 16185756
[TBL] [Abstract][Full Text] [Related]
16. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
17. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation.
Dueñas-Gonzalez A; López-Graniel C; González-Enciso A; Cetina L; Rivera L; Mariscal I; Montalvo G; Gómez E; de la Garza J; Chanona G; Mohar A
Ann Oncol; 2003 Aug; 14(8):1278-84. PubMed ID: 12881393
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
